Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v29i04.5810

THE USE OF BIOLOGICS IN AUTOIMMUNE DISEASE MANAGEMENT: A REVIEW OF RECENT ADVANCES AND CHALLENGES

Abdulmajeed Awadh Almutairi[1*], Majed Saad Alotaibi[1], Mohammed Awadhallah Aljuaid[1], Abdulmohsen Maywdh Alzaidi[1], Ali Hassan Aloufi[2], Mohmmed Hamdi Althomali[3], Turki Fahad Alharthy[4], Yasir Abdul Al Zizi[1], Saeed Atiah Ahmed Alghamdi[5], Mohammed Saif Almuntashiri[6], Nashmeah Abdullah Alshammari[7], Basim Marzoq Al Hejji[1]

[1*]Department of Pharmacy, Children Hospital, Taif, Saudi Arabia
[2] Department of Pharmacy, Mental Health Hospital, Taif, Saudi Arabia
[3]Department of Pharmacy, King Faisal Medical Complex, Taif, Saudi Arabia
[4]Department of Pharmacy, Ministry of Health, Taif, Saudi Arabia
[5]Department of Pharmacy, Namarh General Hospital, Namrah, Saudi Arabia
[6]Department of Pharmacy, Ministry of Health, Alqunfudah, Saudi Arabia
[7]Department of Pharmacy, Al Uwayqilah Hospital, Al Uwayqilah, Saudi Arabia

***Corresponding Author:**Abdulmajeed Awadh Almutairi
*Department of Pharmacy, Children Hospital, Taif, Saudi Arabia, email: al.mowade@hotmail.com

Abstract
Biologic therapies have transformed the treatment landscape for autoimmune diseases by targeting specific components of the immune system, offering new avenues for managing conditions traditionally resistant to conventional therapies. These agents, including monoclonal antibodies, fusion proteins, and cytokines, are tailored to modulate immune pathways directly involved in autoimmune pathogenesis, such as tumor necrosis factor (TNF) and various interleukins. The precision of these therapies significantly improves efficacy and patient outcomes by reducing systemic side effects associated with broader immunosuppressive drugs. Despite the benefits, the administration of biologics is associated with several challenges, including the risk of severe infections, the development of anti-drug antibodies, infusion reactions, and potential long-term effects such as increased cancer risk. These adverse reactions are influenced by the complex pharmacodynamics and pharmacokinetics of biologics, which differ markedly from those of small molecule medications. Biologics are typically administered via injection or infusion, necessitating careful monitoring and management strategies to mitigate risks and manage side effects effectively. Pharmacological insights into the mechanisms of action of biologics reveal that they operate by selectively inhibiting key cytokines and immune cells involved in inflammatory processes. However, this can lead to complications like immunosuppression and the paradoxical induction of other autoimmune phenomena. The potential for drug interactions, particularly with other immunomodulatory agents and live vaccines, adds another layer of complexity to treatment regimens, requiring detailed patient assessments and tailored therapeutic approaches. Given these considerations, it is essential to balance the clinical benefits of biologic therapies against their risks. Ongoing research and real-world evidence continue to refine the use of biologics, aiming to enhance safety profiles and develop management strategies that optimize treatment outcomes for patients with autoimmune diseases.

Keywords: Biological treatment, pharmacodynamics, drug interactions, contraindications, autoimmune

Introduction

Biological drugs, or biologics, are a class of therapeutics derived from living organisms, including humans, animals, or microorganisms. Unlike traditional small molecule drugs, which are chemically synthesized and have well-defined structures, biologics are complex mixtures that are not easily identified or characterized. They include a wide range of products such as monoclonal antibodies, fusion proteins, and cytokines, which are tailored to target specific components of the immune system (1). As such, biologics have emerged as critical agents in the management of autoimmune diseases, where they selectively modulate immune response to prevent the immune system from attacking the body's own tissues. The types of biologics used in autoimmune disease management include monoclonal antibodies (mAbs), which are antibodies engineered to bind specific antigens, cytokines which are small proteins important in cell signaling, and fusion proteins, which are created through the joining of two or more genes that originally coded for separate proteins. Each type is designed to interfere at different points in the immune response, thus offering targeted therapeutic options for a variety of autoimmune conditions (2).

The primary uses of biologics in the field of autoimmune diseases are to reduce symptoms, improve overall health outcomes, and halt the progression of disease by targeting inflammatory pathways that are central to the disease mechanism. For example, TNF inhibitors are used widely in rheumatoid arthritis and Crohn’s disease to block the tumor necrosis factor, a key cytokine involved in systemic inflammation (3). Other biologics, such as interleukin inhibitors and integrin antagonists, have been developed to target different cytokines and cell-adhesion molecules, respectively, expanding the therapeutic options available for various autoimmune conditions. Despite their therapeutic potential, the use of biologics in clinical practice requires careful consideration of their pharmacodynamics and pharmacokinetics. Understanding the mechanisms through which these drugs affect the immune system, their absorption, distribution, metabolism, and excretion, is crucial for optimizing their efficacy and minimizing adverse effects. Furthermore, the complex nature of biologics introduces challenges in production and quality control, making them generally more expensive and less accessible than conventional therapies (4).

As research and development in biologics continue to advance, it is crucial to continually evaluate their efficacy, safety, and mechanisms of action. This paper aims to review the recent advances in biologic therapies for autoimmune disease management, focusing on their pharmacological properties, clinical applications, and the challenges faced in their use.

Methods

For this review we involved a thorough examination of studies conducted in English, utilizing the PubMed, Web of Science, Cochrane and Scopus databases. The analysis aimed to identify assessment methodologies and early warning systems pertinent to the management of dental erosion. Keywords such as "biologics," " pharmacodynamics," and " mechanism of action " directed our systematic search.

Discussion

The pharmacological landscape of biologics in autoimmune disease management has been shaped significantly by advancements in molecular biology and immunology. The targeted nature of biologic therapies offers a distinct advantage over traditional immunosuppressive medications, as they can modulate specific pathways involved in the pathogenesis of autoimmunity without broadly suppressing the immune system. This specificity not only enhances therapeutic efficacy but also minimizes the occurrence of unwanted systemic side effects, a common drawback of conventional therapies (5).

However, the pharmacokinetics of biologics presents unique challenges. Due to their large molecular size and complex structure, biologics are typically administered via parenteral routes, which can

impact patient compliance. Furthermore, their metabolism does not follow the typical pathways associated with small molecule drugs; instead, biologics are often degraded by proteolytic enzymes and cleared via cellular uptake, which can vary significantly among individuals, leading to differences in efficacy and risk of adverse reactions (6). These pharmacokinetic factors necessitate careful dose adjustments and monitoring, complicating their use in clinical practice.

Moreover, the long-term use of biologics can lead to the development of anti-drug antibodies (ADAs), which can neutralize the therapeutic effects of the drugs and exacerbate disease symptoms. The incidence of ADAs varies among different biologics and patient populations, influenced by factors such as drug structure, treatment regimen, and individual patient immune response (7). Addressing this issue remains a critical area for ongoing research, as understanding the mechanisms behind ADA generation could lead to more effective strategies for managing and preventing this complication.

Pharmacodynamics and Mechanisms of Action in Biologic Therapies

Biologic therapies have revolutionized the treatment of autoimmune diseases by providing targeted interventions that modulate specific components of the immune system. The pharmacodynamic actions of these biologics are primarily focused on disrupting the signaling pathways that drive the inflammatory and immune responses characteristic of autoimmune disorders. For example, TNF inhibitors, one of the most widely used classes of biologics, bind to tumor necrosis factor-alpha (TNF-α), a cytokine that plays a pivotal role in inflammation. By neutralizing this cytokine, TNF inhibitors prevent the cascade of inflammatory reactions that contribute to the symptoms and progression of diseases like rheumatoid arthritis and psoriasis (8).

Another class of biologics includes the interleukin inhibitors, which target various interleukins involved in the immune response. For instance, IL-6 inhibitors impede the interleukin-6 pathway, which is critical in the inflammatory process of many autoimmune diseases, including rheumatoid arthritis and Castleman's disease. By blocking IL-6, these drugs reduce both the acute-phase response and the chronic inflammation associated with these conditions (9). Similarly, IL-17 inhibitors have shown efficacy in managing conditions like psoriasis by blocking the activity of interleukin-17, which promotes skin inflammation and keratinocyte proliferation (10).

B cell targeted therapies represent another crucial category. These drugs, including CD20-directed cytolytic antibodies, lead to the depletion of B cells, which are integral to the autoimmune response by producing autoantibodies and presenting antigens. This mechanism is particularly effective in conditions such as systemic lupus erythematosus and multiple sclerosis, where B cells play a critical role in the disease's pathogenesis (11). The precision with which these biologics act not only improves therapeutic outcomes but also reduces the side effects commonly associated with broader immunosuppressive drugs. By understanding the detailed pharmacodynamics of these therapies, clinicians can better predict who will benefit from specific biologics, tailor treatments to individual patient profiles, and manage potential adverse effects more effectively.

Drug Interactions and Contraindications in Biologic Treatment Regimens

Biologic therapies, despite their efficacy, require careful consideration regarding drug interactions and contraindications due to their complex biological nature and specific mechanisms of action. These interactions can affect drug efficacy and safety, making the management of patients on biologic therapies particularly challenging. For example, the concurrent use of biologics with other immunosuppressants like methotrexate is common in conditions such as rheumatoid arthritis. While this combination can enhance therapeutic effects, it also increases the risk of infections and hepatotoxicity, necessitating careful patient monitoring and dose adjustments (12). Furthermore, the interaction between biologics and live vaccines is a significant concern. Biologics that inhibit TNF-α or interleukin pathways can impair the body's immune response to live vaccines, increasing the risk of vaccine-induced diseases. This is especially critical in patients who require vaccinations against pathogens like varicella or yellow fever. Therefore, vaccination status should be assessed and managed before initiating biologic therapy (13).

Contraindications also play a crucial role in the safe administration of biologics. For instance, biologics targeting TNF-α are contraindicated in patients with heart failure, as they can exacerbate the condition. Similarly, patients with a history of demyelinating diseases should avoid certain biologics due to the risk of exacerbating neurological symptoms (14). It is essential for clinicians to evaluate a patient's complete medical history to identify potential contraindications and prevent adverse effects. Additionally, specific patient populations, such as pregnant or breastfeeding women, must be considered carefully when prescribing biologics. The transplacental transfer of certain biologics can potentially affect fetal immune development, and the lack of extensive safety data in these populations makes treatment decisions particularly complex (15). Clinicians must weigh the benefits of treatment against potential risks and, when possible, consult available registries or databases that track outcomes in these patient groups.

Adverse Reactions to Biologics: Pharmacological Insights and Management Strategies

Biologics have transformed the therapeutic landscape for autoimmune diseases, offering targeted interventions that can significantly improve patient outcomes. However, their use is not without risks, as these agents can induce a range of adverse reactions that vary in severity and incidence. Understanding these reactions and their underlying pharmacological mechanisms is critical for developing effective management strategies.

One of the most common adverse reactions associated with biologics is the risk of infection. Given their mode of action, which often involves suppression of specific immune pathways, patients are at an increased risk of both common and opportunistic infections. For example, TNF inhibitors can predispose patients to tuberculosis and other bacterial infections due to their critical role in granuloma formation and macrophage activation (16). Management strategies include rigorous screening for latent infections before initiating therapy and continuous monitoring during treatment. Another significant adverse reaction is the development of infusion reactions, which can range from mild to severe, including anaphylaxis. These reactions are thought to be either immune-mediated or non-immune-mediated hypersensitivity reactions to the biologic agent. Pre-medication with corticosteroids, antihistamines, and acetaminophen, along with gradual escalation of the infusion rate, can effectively reduce the incidence and severity of these reactions (17).

Additionally, biologics can induce autoimmune conditions, paradoxically given their use in treating such conditions. This phenomenon is likely due to the complex interplay of cytokine inhibition, which may disrupt immune tolerance and lead to the production of autoantibodies. For instance, patients treated with interferon-β and TNF inhibitors have developed symptoms of psoriasis and lupus-like syndrome, respectively (18). The management of these conditions involves discontinuing the offending agent and, if necessary, treating with corticosteroids or other immunosuppressants. Lastly, the long-term use of biologics has been associated with an increased risk of malignancies, particularly lymphoma and skin cancers. The exact mechanism remains under investigation, but chronic immunosuppression and the specific immunological effects of the biologics are likely contributors (19). Clinicians must balance the benefits of biologic therapy against these risks, employing regular cancer screenings and vigilant monitoring.

References

1. Chang C, Tanaka A, Bowlus C, Gershwin ME. The use of biologics in the treatment of autoimmune liver disease. Expert Opinion on Investigational Drugs. 2020 Apr 2;29(4):385-98.
2. Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal immunology. 2018 Nov 1;11(6):1558-70.
3. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC medicine. 2013 Dec;11:1-2.
4. Boraschi D, Penton-Rol G. Pharmacological Strategies Using Biologics as Immunomodulatory Agents. Immune Rebalancing. 2016 Jan 1:1-1.
5. Parnham MJ, Nijkamp FP, editors. Principles of immunopharmacology. Birkhäuser Verlag; 2005.

6. Shi S. Biologics: an update and challenge of their pharmacokinetics. Current Drug Metabolism. 2014 Mar 1;15(3):271-90..
7. Cludts I, Spinelli FR, Morello F, Hockley J, Valesini G, Wadhwa M. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine. 2017 Aug 1;96:16-23.
8. Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opinion on Drug Metabolism & Toxicology. 2019 Nov 2;15(11):913-25.
9. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacology & therapeutics. 2014 Feb 1;141(2):125-39.
10. Zeichner JA, Armstrong A. The role of IL-17 in the pathogenesis and treatment of psoriasis. The Journal of clinical and aesthetic dermatology. 2016 Jun;9(6 Suppl 1):S3.
11. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology. 2006 May 1;6(5):394-403.
12. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. The Journal of Rheumatology. 2006 Dec 1;33(12):2398-408.
13. Simonetti O, Rizzetto G, Molinelli E, Diotallevi F, Radi G, Cirioni O, D'Errico MM, Offidani A. Safety and efficacy of vaccines during COVID-19 pandemic in patients treated with biological drugs in a dermatological setting. InHealthcare 2021 Apr 1 (Vol. 9, No. 4, p. 401). MDPI.
14. Dogra S, Khullar G. Tumor necrosis factor-α antagonists: Side effects and their management. Indian Journal of Dermatology, Venereology and Leprology. 2013 Jul 1;79:35.
15. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014 Aug 1;53(8):1377-85.
16. Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the rheumatic diseases. 2020 Dec 1;79(12):1532-43.
17. Sitek A, Chiarella SE, Pongdee T. Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management. Frontiers in Allergy. 2023 Aug 11;4:1219735.
18. Ramos-Casals M, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmunity reviews. 2010 Jan 1;9(3):188-93.
19. Drosos AA, Pelechas E, Kaltsonoudis E, Markatseli TE, Voulgari PV. Biologic therapies and autoimmune phenomena. mediterranean Journal of Rheumatology. 2021 Jun;32(2):96.